Show
Sort by
-
Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population
-
Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population
-
Detection of vertebral fractures on routine chest rays: The stof study
-
Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment
-
Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition
-
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
-
Healthcare consumption and direct costs of rheumatoid arthritis in Belgium
-
- Journal Article
- A1
- open access
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
-
Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients
-
DAS28 is a robust measure of the physician's clinical judgment of response infliximab therapy